Archive:

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business. Staad, 7 September 2022 – Biosynth Carbosynth, vivitide and Pepscan are pleased to announce today their rebranding to Biosynth to match their parent group and the launch of their site at www.biosynth.com. Biosynth is a global supplier of critical products and services to the life sciences industry, across the areas of complex chemicals, quality peptides and key biological reagents. In combination with their research …

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.  Staad, 30 June 2022 – Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services. Biosynth’s ability to deliver chemical manufacturing services “from the first idea to the finished product” is now matched in peptides, with Pepscan’s expertise in both …

Lelystad, the Netherlands, June 28, 2022 – Pepscan, the all-in-one peptide service provider, is excited to announce that it will supply personalized peptide pools for six patients in a phase I trial led by Mayo Clinic principal investigator Yanyan Lou, M.D., Ph.D., in collaboration with Keith L. Knutson, Ph.D. The trial tests the safety and tolerability of an experimental personalized peptide vaccine when given in combination with pembrolizumab in treating patients with a wide range of advanced solid tumors and …

Hans Langedijk on dedication and persistence in scientific research “First, we need to understand a disease before we can take the step towards discovery and development of a treatment. To gain functional understanding of the disease mechanisms of pathogens, such as viruses, a lot of data is needed. And that’s exactly what the Pepscan epitope mapping method has to offer,” says Hans Langedijk, former Senior Scientist and Project Leader at Pepscan. After receiving his master’s degree in Chemistry from the …

Pepscan, the all-in-one peptide service provider with proprietary constraining technologies, is excited to announce that its specialists will manufacture the personalized peptide pools for the treatment of cancer patients in Evaxion’s phase IIb trial. Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, recently published the initial results of the peptide-based personalized therapy EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal …

Wim Schaaper (PhD) on early improvement engineering “Which opportunities do we see that would further improve our peptide library technology and make it even more effective? This was a returning topic on the Pepscan agenda and for me personally a very nice challenge to work on,” says Wim Schaaper, Senior Scientist at Pepscan from 2001 till his retirement in 2017. Currently Pepscan has, as many companies, a team of improvement engineers. Wim Schaaper is considered the companies’ first improvement engineer, …

Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced a strategic research collaboration with Fusion Pharmaceuticals to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Pepscan’s unique CLIPS™ phage display platform will screen billions of peptides to discover highly constrained de novo peptides with enhanced affinities, selectivities, and proteolytic stabilities. “We are pleased to partner with Pepscan, a global leader in peptide discovery with a platform that will enable us to create novel, …

At Pepscan, we help you guide your peptide project through the various stages of development towards clinical application and commercialization. To support the growing number of customers looking for mid-sized batches of custom-made (GMP) peptides, Pepscan has extended our column purification technology with a mid-sized column packer. “This technology significantly reduces purification time compared to the methodology for smaller batch sizes,” explains Richard van Duinkerken, Purified Peptides team lead. “This new equipment ensures that we can keep providing our clients …

Jan Langeveld (PhD) on how luck, international collaboration and “pur sang” research led to success. In 1990, Jan Langeveld joined forces with Rob Meloen, who later became Pepscan’s founder but at the time was working for the Institute for Animal Science and Health in Lelystad. For Langeveld, the Pepscan technique seemed a quick and cheap way to unravel antibody specificity, and represented a revolution in our understanding of protein structure and function. At the time, Meloen was also expecting progress …